ETAP-Lab is a preclinical CRO renowned for its expertise in the fields of dermatology, neurology, cardiology and gastroenterology. It assesses the effectiveness of drug candidates and medical devices.

Founded in 1991, ETAP-Lab has now worked with 150 companies ranging from small biotechs to large pharmaceutical groups, both in France and further afield. Ever since the company’s earliest days, ETAP-Lab models have consistently offered high translational value associated with relevant protocols. Mainly comprised of scientific experts, our team analyses client requirements, offering guidance and advice in the development of a tailor-made solution.

ETAP-Lab studies are conducted to exacting quality standards, ensuring the reproducibility, transparency and traceability of tests while maintaining responsiveness and offering regular dialogue with our project managers.

ETAP-Lab can fast-track your pipeline with preclinical excellence having high predictability level through in vitro and in vivo testing and rodent behavioural analysis:

– DERMATOLOGY: Wide portfolio of original inflammatory (psoriasis, atopic dermatitis) and wound-healing in vivo models.

– CARDIOLOGY: In-depth in vivo studies of major cardiovascular diseases like Pulmonary Arterial Hypertension, Ischemia Reperfusion, and Heart failures.

– NEUROLOGY: Original and translational in vivo and in vitro models of Stroke and neurodegenerative diseases like Alzheimer’s and Parkinson’s models.

– GASTROENTEROLOGY: In vivo models of gastrointestinal disorders like irritable bowel syndrome (IBS) and traveler’s diarrhea. Expertise in metabolic disturbances such as diabetes, obesity, and malnutrition.

– Therapeutic areas: Dermatology, Neurology, Cardiology, Gastroenterology, Metabolism

– Based in: Production sites in France

– Employees: 11 – 50

– Created in: 1991